Literature DB >> 9129137

Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth.

K Iwase1, B M Evers, M R Hellmich, H J Kim, S Higashide, D Gully, C M Townsend.   

Abstract

The effect of the nonpeptide neurotensin (NT) receptor antagonist SR48692 on NT-mediated growth of xenografted human colon cancers (LoVo) was determined. Sixty-four athymic nude mice, inoculated with LoVo cells at a single site, were randomized into four groups of 16 mice each to receive either vehicle NT (600 microg/kg), SR48692 (2 mg/kg) or NT+SR48692 administered s.c., t.i.d., for 25 days. Treatment with NT significantly stimulated LoVo tumour growth, weight, DNA and protein content; SR48692 blocked this NT-mediated effect but had no effect when administered as a single agent. In addition, normal jejunum and ileum were removed and assessed. Similar to the effects on LoVo tumours, NT stimulated jejunal and ileal growth; SR48692 blocked this NT-mediated effect. In contrast to our in vivo findings, NT had no effect on LoVo cell growth in vitro. Also, Northern blot analysis demonstrated no expression for the NT receptor in either LoVo tumour cells or xenografted tumours. Our findings suggest that the trophic effect of NT on LoVo may be through an indirect effect; one possibility is that administration of NT may stimulate the release of other trophic factors which then stimulate tumour growth. The nonpeptide NT receptor antagonist SR48692 will be a useful agent to delineate the specific effects of NT on neoplastic as well as normal gastrointestinal tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9129137     DOI: 10.1016/s0960-7404(96)80028-4

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.

Authors:  Yanli Zhang; Shunqin Zhu; Liang Yi; Yaling Liu; Hongjuan Cui
Journal:  Mol Cell Biochem       Date:  2013-12-20       Impact factor: 3.396

3.  Gut peptide receptor expression in human pancreatic cancers.

Authors:  R A Ehlers; Sh Kim; Y Zhang; R T Ethridge; C Murrilo; M R Hellmich; D B Evans; C M Townsend; B Mark Evers
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

Review 4.  A Review of the Role of Neurotensin and Its Receptors in Colorectal Cancer.

Authors:  Shengyang Qiu; Gianluca Pellino; Francesca Fiorentino; Shahnawaz Rasheed; Ara Darzi; Paris Tekkis; Christos Kontovounisios
Journal:  Gastroenterol Res Pract       Date:  2017-02-20       Impact factor: 2.260

5.  The role of neurotensin as a novel biomarker in the endoscopic screening of high-risk population for developing colorectal neoplasia.

Authors:  Christos Kontovounisios; Shengyang Qiu; Shahnawaz Rasheed; Ara Darzi; Paris Tekkis
Journal:  Updates Surg       Date:  2017-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.